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Study Design: Retrospective patient data collection and investigator survey.
Purpose: To investigate patterns of opioid treatment for pain caused by spinal disorders in Korea.
Overview of Literature: Opioid analgesic prescription and adequacy of consumption measures in Korea have markedly increased 
in the past decade, suggesting changing patterns in pain management practice; however, there is lack of integrated data specific to 
Korean population. 
Methods: Patient data were collected from medical records at 34 university hospitals in Korea. Outpatients receiving opioids for 
pain caused by spinal disorders were included in the study. Treatment patterns, including opioid types, doses, treatment duration, 
outcomes, and adverse drug reactions (ADRs), were evaluated. Investigators were interviewed on their perceptions of opioid use for 
spinal disorders.
Results: Among 2,468 analyzed cases, spinal stenosis (42.8%) was the most common presentation, followed by disc herniation (24.2%) 
and vertebral fracture (17.5%). In addition, a greater proportion of patients experienced severe pain (73.9%) rather than moderate 
(19.9%) or mild (0.7%) pain. Oxycodone (51.9%) and fentanyl (50.8%) were the most frequently prescribed opioids; most patients 
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Introduction
Spine and back pain are among the most common sources 
of chronic noncancer pain among adults. Low back pain 
is a globally prevalent concern, with an estimated lifetime 
prevalence of approximately 40% [1]. The UK National 
Institute for Health and Care Excellence and the Ameri-
can College of Physicians/American Pain Society (ACP/
APS) guidelines provide recommendations for managing 
chronic low back pain through various pharmacologi-
cal and nonpharmacological treatment modalities [2,3]. 
Despite the variety of treatment modalities in use, a con-
siderable amount of needs in chronic pain management 
remain unmet. For example, pain-relieving medications 
were estimated to be the most commonly prescribed 
pharmacotherapy in ambulatory care in the United States 
(US) [4].
Pharmacotherapies recommended by the ACP/APS 
guidelines for subacute and chronic back pain include ac-
etaminophen, benzodiazepine, tramadol, and opioids [2]. 
Opioids are considered effective for reducing nociceptive 
pain and are moderately effective for neuropathic pain; 
however, tolerability issues such as nausea and vomiting 
tend to limit their application in clinical practice. Despite 
these limitations, opioids can be both effective and safe, if 
appropriately used [3,5].
Long-term use of opioids for chronic noncancer pain 
remains controversial owing to concerns regarding an-
algesic tolerance and drug dependence [6-10]. The ratio 
of opioid to total analgesic use in Korea is still relatively 
low compared with Western countries. In a study evaluat-
ing the adequacy of opioid use at the national level with 
the Adequacy of Consumption Measure (ACM), Korea 
was listed with a 47.0% adequacy score for opioid con-
sumption in 2010 [11]. This implies that less than half 
of the patients in Korea who required opioid treatment 
actually received it. In 2010, the adequacy scores of other 
countries were as follows: USA, 229.7%; Canada, 312.6%; 
France, 73.5%; UK, 66.4%; Japan, 15.5%; and China, 1.2% 
[11]. This indirectly indicates limited usage of opioids for 
management of spinal pain in Korea.
Nevertheless, opioid usage in Korea is growing rapidly. 
The adequacy level of opioid consumption, as indicated by 
the ACM, has increased by over six-fold during the 2006–
2010 period [11,12]. Such a remarkable improvement 
suggests changing attitudes toward pain management 
[9]. Considering the lack of integrated data specific to the 
Korean population, we sought to better understand the ef-
fectiveness and safety of opioid use in the management of 
different types of spinal pain arising from multiple causes 
[5,13]. 
This retrospective study was designed to investigate the 
following: (1) patterns of opioid usage in patients with 
pain caused by spinal disorders; (2) physicians’ percep-




Since this study was a retrospective study, the Institutional 
Review Boards of the 34 participating hospitals approved 
the study and granted waiver for collecting informed con-
sent from patients. All information was anonymized in 
order to maintain patient confidentiality. Data were col-
lected from medical records of 34 university hospitals in 
Korea. The list of patients was acquired from August 2011 
were prescribed relatively low doses. The median duration of opioid treatment was 84 days. Pain relief was superior in patients with 
longer treatment duration (≥2 months) or with nociceptive pain than in those with shorter treatment duration or with neuropathic or 
mixed-type pain. ADRs were observed in 8.6% of cases. According to the investigators’ survey, “excellent analgesic effect” was a 
perceived advantage of opioids, while safety concerns were a disadvantage.
Conclusions: Opioid usage patterns in patients with spinal disorders are in alignment with international guidelines for spinal pain 
management. Future prospective studies may address the suitability of opioids for spinal pain treatment by using appropriate objec-
tive measurement tools.
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database, which included patients who visited hospitals 
due to spinal disorders in November 2010 or earlier, with 
an aim to collect data of more than 50 patients per investi-
gator. In outpatient clinics with <50 patients in November 
2010, patients from the preceding month were included 
until the number reached 50. The investigators reviewed 
patient medical records and extracted information includ-
ing demographics, diagnoses, type and dose of the pre-
scribed opioids, and comorbidities. Korean outpatients of 
both sexes, aged ≥20 years, who received opioids at least 
once to treat pain arising from spinal diseases in Novem-
ber 2010 or earlier were eligible for inclusion. 
Exclusion criteria were used to eliminate cases wherein 
external factors may have influenced clinical decisions 
regarding opioid usage. Any patient participating in an in-
terventional study during the study period was excluded. 
In addition, patients with cancer-related pain caused by 
primary or metastatic spinal cancer were excluded. In or-
der to minimize selection bias, 50 consecutive cases were 
enrolled per investigator from the patients who met the 
selection criteria. 
2. Definitions
Spinal disorders assessed in this study included, but were 
not limited to, spinal stenosis, disc herniation, vertebral 
fracture, persistent postoperative back pain, unspecified 
back pain, intervertebral disc disorders, spondylolisthesis, 
spinal cord injury, and spinal infection. Diagnosis was 
considered as a multiple-option item in the case report 
form because the medical records often described more 
than one spinal condition per patient.
Opioid analgesics included, but were not limited to, 
oxycodone (immediate release [IR], prolonged release 
[PR], and other composite formulations), fentanyl, hy-
dromorphone, and codeine in combination with acet-
aminophen and ibuprofen. These commercially available 
medications are classified as “narcotics” by the Act on the 
Control of Narcotics, the Enforcement of Decree of the 
Act on the Control of Narcotics, and other relevant laws 
in Korea. A codeine combination is classified as a narcotic 
in Korea, but codeine is otherwise classified as a weak 
opioid according to the analgesic ladder published by the 
World Health Organization [14].
Pain intensity was recorded using a numeric rating scale 
(NRS [15,16]) where available. NRS scores were converted 
into following categories: “severe pain” for scores 7–10, 
“moderate pain” for scores 4–6, and “mild pain” for scores 
1–3. In cases where no NRS values were recorded, pain in-
tensity was assessed as severe, moderate, or mild accord-
ing to the descriptions in the medical records. Pain in-
tensity was examined at the initiation of opioid treatment 
and 1 and 2 months after treatment initiation. Moreover, 
adverse drug reactions (ADRs) after opioid administra-
tion were recorded.
3. Investigators’ questionnaire
Participating investigators and subinvestigators were in-
terviewed to assess their perceptions regarding the usage 
of opioid analgesics. Investigators were also asked about 
their concerns regarding opioid dependency and their ex-
periences with dependent patients. In addition, they were 
asked to suggest actions or measures that may improve 
opioid usage in Korea.
4. Statistical analyses
Descriptive statistics were used to summarize patient 
characteristics and opioid treatment patterns. Means and 
standard deviations or medians and ranges were used 
for continuous data. Categorical data were presented as 
numbers and percentages. The number of cases and the 
percentages of ADRs were presented as well. Results of 
the investigators’ questionnaire were descriptively sum-
marized.
Pearson’s chi-square test was used to identify statisti-
cally significant relationships (1) between type of pain ex-
perienced and presence/absence of pain relief with opioid 
treatment and (2) between duration of opioid treatment 
and presence/absence of pain relief. All reported p-values 
were two sided; p-values <0.05 were considered signifi-
cant. Statistical analyses were performed using SAS ver. 9.1 
(SAS Institute, Cary, NC, USA). 
Results
1. Baseline characteristics
In total, data regarding 2,483 cases were collected from 34 
hospitals. Of these, 2,468 cases were analyzed after exclud-
ing 15 cases with protocol violations. Table 1 summarizes 
patient characteristics. The study population contained 
more female (60.0%) than male (40.0%) patients, and 
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the mean age was 64.2 years. Spinal stenosis (42.8%) was 
the most common diagnosis, followed by disc herniation 
(24.2%), vertebral fracture (17.5%), persistent postopera-
tive back pain (13.0%), and unspecified back pain (10.7%).
Of the 2,468 patients analyzed, 694 (28.1%), 635 (25.7 
%), and 1,027 (41.6%) patients reported neuropathic, no-
ciceptive, and mixed (both neuropathic and nociceptive) 
pain, respectively. Before initiating opioid therapy, 1,823 
(73.9%) patients experienced severe pain, 490 (19.9%) ex-
perienced moderate pain, whereas 18 (0.7%) experienced 
mild pain. Only 593 (24.0%) patients underwent an NRS 
assessment of pain intensity; the mean pain score was 
7.5. The results majorly indicated severe pain levels in the 
study population.
The duration of pain before initiating opioid treatment 
was <3 months in 865 (35.0%) patients, 3–12 months in 
473 (19.2%) patients, and ≥12 months in 962 (39.0%) pa-
tients (Table 1).
2.  Nonopioid analgesia before initiation of opioid 
treatment
Over half of the patients (1,389/2,468; 56.3%) were 
treated with nonopioid analgesics before receiving opi-
oids for spinal pain. Of these, 847 (34.3%) patients had 
received weak opioids (including tramadol), 639 (25.9%) 
patients had received nonsteroidal anti-inflammatory 
drugs (NSAIDs), and 264 (10.7%) patients had received 
anticonvulsants.
3. Opioid treatment patterns
Prescriptions were classified as regular or pro re nata 
(PRN). In 2,060 (83.5%) patients, opioid therapy was 
administered regularly, whereas in 408 (16.5%) patients, 
it was prescribed only when required. The opioid types 
prescribed, daily doses, and treatment duration for each 
opioid analgesic are summarized in Table 2. Oxycodone 
(PR, IR, and other composite drugs combined) was the 
most commonly prescribed drug (in 51.9% patients), 
followed by fentanyl (50.8%) and codeine combinations 
(20.0%). The median daily dose of fentanyl was 12.0 μg/
hr (range, 10.0–75.0 μg/hr), while the median daily doses 
of oxycodone PR and IR were 20.0 mg (range, 5.0–200.0 
mg) and 10.0 mg (range, 5.0–60.0 mg), respectively. The 
median daily dose of codeine combinations was 30.0 mg 
(range, 10.0–80.0 mg). The patients in this study had re-
ceived relatively low-dose opioid prescriptions according 
to the recommendations of the Korean Ministry of Health 
and Welfare’s 2012 Cancer Pain Treatment Guideline [17]. 
The median treatment duration of fentanyl, oxycodone 
PR, and codeine combinations was 67, 120, and 46 days, 
respectively. 
Table 1. Patient characteristics (n=2,468)
Characteristic No. (%)
Demographic information
   Age (mean±SD), yr  64.2±14.1
   Sex
      Male   986 (40.0)
      Female 1,482 (60.0)
Diagnosis (multiple diagnoses possible)
   Spinal stenosis 1,056 (42.8)
   Disc herniation   597 (24.2)
   Vertebral fracture   431 (17.5)
   Persistent postoperative back pain   320 (13.0)
   Unspecified back pain   264 (10.7)
   Intervertebral disc disorders  211 (8.6)
   Spondylolisthesis  204 (8.3)
   Spinal cord injury  100 (4.1)
   Spinal infection   46 (1.9)
   Others   457 (18.5)
Type of pain
   Neuropathic pain only   694 (28.1)
   Nociceptive pain only   635 (25.7)
   Both neuropathic and nociceptive pain 1,027 (41.6)
   No information  112 (4.5)
Pain intensity at the initiation of 
opioid treatment
   Severe 1,823 (73.9)
   Moderate   490 (19.9)
   Mild   18 (0.7)
   No information  137 (5.6)
Duration of pain prior to the initiation 
of opioid treatment
   <3 mo   865 (35.0)
   3 to 12 mo   473 (19.2)
   ≥12 mo   962 (39.0)
   No information  168 (6.8)
SD, standard deviation.
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4.  Opioid treatment outcomes and relationships with 
pain type and treatment duration
Achievement of pain relief with opioid treatment was 
significantly related to the type of pain. The proportion of 
patients experiencing pain relief differed across the three 
types of pain, and the difference was significant (p<0.0001) 
(Table 3). The proportion of patients who experienced 
pain relief was highest in the group with nociceptive pain 
alone (63.3%), followed by that with neuropathic pain 
alone (56.5%) and that with mixed-type pain (47.0%) 
(Table 3).
Moreover, achievement of pain relief was significantly 
related to opioid treatment duration (<1 month, 1–2 
months, and ≥2 months); statistically significant differ-
ences were noted across all three treatment duration cat-
egories (p=0.0013) (Table 4). In comparison with shorter 
treatment durations, treatment duration of ≥2 months 
resulted in a greater proportion of patients experiencing 
pain relief (Table 4).
5. Concomitant treatment for spinal pain management
Of the 2,468 patients, 1,467 (59.4%) patients received 
concomitant treatment with surgery, physical therapy, or 
nonsurgical interventions for pain control in addition to 
opioid therapy. Concomitant analgesics were prescribed 
in 1,513 (61.3%) patients. The most frequently prescribed 
concomitant drug was tramadol in 779 (31.6%) patients, 
followed by NSAIDs in 685 (27.8%) patients and anticon-
Table 2. Opioid types, dosages and treatment durations (n=2,395a))
Opioid type No. (%)
Daily dose Duration of treatment (day)
Mean±SD Median (range) Mean±SD Median (range)
Overall   2,395 (100.0) - - 272.6±401.9     84.0 (1.0, 6, 148.0)
Oxycodone 1,242 (51.9) - - - -
   PR   779 (32.5)   26.2±15.9 mg   20.0 (5.0, 200.0) 282.6±398.1 120.0 (1.0, 2966.0)
   IR   449 (18.7) 12.8±8.0 mg 10.0 (5.0, 60.0) 147.7±273.8   36.0 (1.0, 2377.0)
   Oxycodone (others)b)   14 (0.6) 13.9±2.1 mg   15.0 (10.0, 15.0) 542.9±571.7   215.0 (12.0, 1447.0)
Fentanylc) 1,217 (50.8)    17.6±8.9 μg/hr   12.0 (10.0, 75.0) 252.1±348.9    67.0 (1.0, 2,161.0)
Codeine combinationd)   479 (20.0)   32.6±14.0 mg   30.0 (10.0, 80.0) 186.3±376.4   46.0 (1.0, 5551.0)
Hydromorphone  115 (4.8)   8.9±4.3 mg   8.0 (2.0, 30.0) 94.2±104.8 57.0 (1.0, 709.0)
Morphine   64 (2.7)   34.7±26.1 mg     20.0 (10.0, 120.0) 209.0±443.1   31.0 (2.0, 2556.0)
Hydrocodone   14 (0.6) 21.5±2.6 mg   22.5 (15.0, 22.5) 103.1±142.4 29.0 (8.0, 464.0)
SD, standard deviation; PR, prolonged release; IR, immediate release.
a)Data on the type of opioids, dosages and treatment durations were not obtainable from 73 patients; b)Oxycodone (others) indicates composite drugs; 
c)Units for fentanyl are expressed as μg/hr; d) The dose refers to the quantity of codeine in the codeine combination.
Table 3. Proportion of patients experiencing pain relief with opioid analgesic treatment by type of pain (n=1,945)
Type of pain No.
Experienced pain relief with opioid analgesic treatmenta)
Yes No
Overall 1,945b) 1,055 (54.2) 890 (45.8)
Nociceptive pain only  504    319 (63.3)c) 185 (36.7)c)
Neuropathic pain only  620    350 (56.5)c) 270 (43.5)c)
Both neuropathic and nociceptive pain  821    386 (47.0)c) 435 (53.0)c)
Values presented in parentheses are %.
a)Pearson’s chi-square test was used to test for statistically significant association between type of pain and experience of pain relief with treat-
ment (Yes/No) (p=0.001); b) Data on the type of pain and experience of pain relief (Yes/No) were not obtainable for 523 patients; c) Percentages given 
in brackets indicate the proportion that experienced pain relief (Yes/No) for each type of pain.
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vulsants in 389 (15.8%) patients (Table 5). 
6. Investigator survey results
Investigators’ perceptions regarding opioid treatment for 
spinal disorders are presented in Table 6. In total, 75 in-
vestigators and subinvestigators responded to the survey. 
Of these respondents, 30 (40.0%) had expertise in ortho-
pedics, 25 (33.3%) in neurosurgery, 18 (24.0%) in anesthe-
siology and pain medicine, and 2 (2.7%) in rehabilitation 
medicine. 
Among these, 72 (96.0%) respondents perceived “excel-
lent analgesic effect” as the primary advantage of opioid 
analgesics in outpatient clinics; 50 (66.7%) investiga-
tors responded that “concern for early side effects” was 
a disadvantage of opioid analgesics. “Long-term safety 
concerns including drug dependence” were chosen by 34 
(45.3%) respondents, and 60 (80.0%) investigators had 
experienced patients with opioid dependence; however, 
most (81.7%) investigators answered that true cases of 
Table 4. Proportion of patients experiencing pain relief with opioid analgesic treatment by duration of treatment (n=2,037)
Duration of treatment No.
Experienced pain relief following opioid analgesics administrationa)
Yes No
Overall 2,037b) 1,087 (53.4) 950 (46.6)
<1 mo    611    296 (48.5)c) 315 (51.6)c)
1–2 mo    254    125 (49.2)c) 129 (50.8)c)
≥ 2 mo 1,172    666 (56.8)c) 506 (43.2)c)
Values presented in parentheses are %.
a)Pearson’s chi-square test was used to test for statistically significant association between opioid therapy duration and experience of relief (Yes/
No) (p=0.013); b) Data on the duration of opioid therapy and experience of pain relief (Yes/No) were not obtainable for 431 patients; c)Percentages 
given in brackets indicate the proportion experiencing pain relief (Yes/No) for each treatment duration category.
Table 5. Concomitant treatment for management of spinal pain in addition to opioid treatment (n=2,468)
Category (details) No. (%)
Concomitant non-pharmacological therapy for management of spinal pain other than opioid treatment
    Yes 1,467 (59.4)
Non-surgical intervention    927 (37.6)
Surgical treatment    521 (21.1)
Physical therapy    439 (17.8)
Chinese medicine (acupuncture, moxibustion, 
heat/ice pack, herbal medicine)
     53 (2.1)
Others    100 (4.1)
    No    897 (36.4)
    No information    104 (4.2)
Concomitant pharmacotherapy for management of spinal pain besides opioid treatment
    Yes 1,513 (61.3)
Tramadol and tramadol Combinations    779 (31.6)
Non-steroidal anti-inflammatory drugs    685 (27.8)
Anticonvulsants    389 (15.8)
Others    404 (16.4)
    No    955 (38.7)
    No information        0 (0.0)
NSAIDs, non-steroidal anti-inflammatory drugs.
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drug dependence were rarely observed.
For improved use of opioid analgesics, a majority of 
investigators suggested solutions such as “development of 
drugs with fewer side effects and easier titration” (76.0%) 
and “guidelines and clinical data applicable to the Korean 
population” (70.7%).
7. Adverse drug reactions
Of the 2,468 patients eligible for analysis, 211 patients 
(of 2,468 [8.6%] patients, 259 cases) experienced ADRs 
wherein opioid analgesic-related causality could not be 
ruled out. ADR severity was mild in 49.7% (157/259) cas-
es, moderate in 21.2% (67/259) cases, and severe in 11.1% 
(35/259) cases. The three most frequently reported ADRs 
were vomiting, constipation, and dizziness (Table 7).
Discussion
This study aimed to provide an original integrated set of 
Table 6. Investigators’ perceptions and suggestions regarding opioid analgesic use in Korea (n=75)
Category (details) No. (%)a)
Perceived advantages of opioid analgesic prescription in outpatient clinics
    Excellent analgesic effect 72 (96.0)
    Useful for controlling persistent pain following surgery 42 (56.0)
    Useful for patients in whom surgery is prohibitively difficult 36 (48.0)
    Useful as a conservative preoperative treatment 20 (26.7)
    Others 1 (1.3)
Perceived drawbacks of opioid analgesic prescription in outpatient clinics
    Concerns for early side effects 50 (66.7)
    Long-term safety concerns, including drug dependence 34 (45.3)
    Ongoing side effect concerns 33 (44.0)
    Short reimbursement period 21 (28.0)
    Complex administrative processes including issuance of opioid prescription 19 (25.3)
    Burdensome procedure required for explanation to patients 18 (24.0)
    Others 2 (2.7)
Suggestions for better opioid analgesic use
    Development of drugs with fewer side effects and easier titration 57 (76.0)
    Development of guidelines and better clinical data applicable to Koreans 53 (70.7)
    Better administrative conditions including reimbursement and regulations 38 (50.7)
    Meetings for idea exchange and education regarding analgesic use 28 (37.3)
    Others 1 (1.3)
a)Respondents comprised 75 principal investigators and sub-investigators participating in this study. Areas of expertise include Orthopaedics, Neuro-
surgery, Anaesthesiology and Pain Medicine, and Rehabilitation Medicine.
Table 7. Incidence of adverse drug reactions (n=2,468)
Adverse drug reaction (ADR)a) No. (%)
Total number of patients with ADRs 211 (8.6)
   Vomiting   85 (3.4)
   Constipation   64 (2.6)
   Dizziness   30 (1.2)
   Somnolence   15 (0.6)
   Pruritus   12 (0.5)
   Gastrointestinal disorder     7 (0.3)
   Dyspepsia     5 (0.2)
   Abdominal discomfort     3 (0.1)
   Headache     3 (0.1)
   Decreased appetite     3 (0.1)
a)ADRs considered as possibly related to the administration of opioid 
analgesics are shown in the table above. Multiple ADRs could be 
recorded for individual patients. Only the 10 most frequently reported 
ADRs are listed.
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data on the issue of opioid treatment practice for spinal 
pain in Korea. Through a nationwide investigation to 
observe treatment patterns across the country, this study 
achieved its primary goals with a large cohort of 2468 pa-
tients. 
The management of spinal pain requires active treat-
ment plans and implementation. Recommended treat-
ment modalities for spinal pain management can be clas-
sified into four categories: interventional pain therapies, 
complex medication (including opioids and neuropathic 
pain medications), high-intensity cognitive behavioral 
therapy-based programs, and spinal surgery [18]. Despite 
various treatment modalities, there has been very limited 
systematic research to guide and improve the use of opi-
oid analgesics for managing spinal disorder-associated 
pain. This may be a reason for conservative opioid pre-
scription practices. For example, an observational study 
that examined opioid use for spinal and radicular pain 
in 25,479 patients revealed that only 3.4% (867) patients 
were treated with opioids [6].
In a manual guiding the use of opioids for persistent 
pain, the British Pain Society (BPS) recommends strict 
restrictions on the use of strong opioids [19]. The guide-
lines state that (1) opioids should not be used as a first-
line treatment, (2) patients should be adequately informed 
about the long-term effects of opioids, including the pos-
sibility of adverse events, (3) mental health history should 
be recorded before treatment to aid exclusion of patients 
with depression or substance misuse disorders, and (4) 
whenever possible, modified-release opioid formulations 
at regular intervals should be used. In addition, the BPS 
guidelines for low back pain recommend that the lowest 
dose possible should be used for the shortest time possible 
[18,19]. Other recent guidelines and physician resources 
for opioid prescription, such as guidelines from the Cen-
ters for Disease Control and Prevention and the UK Royal 
College of Anaesthetists, state that opioids are not effec-
tive for long-term use [20,21]. 
Our results indicate that the current prescribing prac-
tice in Korea is generally in alignment with the BPS 
guidelines in terms of opioid dosage. Most cases in our 
study were prescribed daily doses of opioids that were in 
the lowest range recommended in the Korean Ministry of 
Health and Welfare’s Cancer Pain Treatment Guidelines 
[17]; however, our data also revealed that 50% of patients 
had received opioid analgesics for >3 months, which may 
be attributed to the lack of adequate treatment options for 
chronic pain.
This study indicates that opioid analgesics are a more 
appropriate treatment option for nociceptive pain than for 
neuropathic or mixed-type pain. In general, opioids are 
known to be excellent pain relievers, particularly for noci-
ceptive pain. In addition, higher opioid doses are needed 
more often for treatment of neuropathic pain than for no-
ciceptive pain [22]. Therefore, the results from this study 
are in agreement with the existing knowledge; however, 
we note that our observations regarding the type of pain 
could be alternatively interpreted, that is, patients with 
neuropathic or mixed-type pain may generally not have 
had the opportunity to receive more optimal treatment 
with opioids or concomitant adjuvants to reach adequate 
levels of pain control. 
To the best of our knowledge, there are no local reports 
dedicated to physician surveys investigating opioid usage 
for managing spinal pain. The results of our investigators’ 
survey suggest that Korean physicians adequately under-
stand the efficacy parameters of opioid usage; however, 
they are concerned regarding the safety issues such as 
addiction although the ADRs from opioid usage in this 
study were limited to 8.6%, and there were no reports of 
actual addiction. These concerns may contribute to the 
modest opioid usage index in Korea, which is still below 
50% [22]. Although the guidelines for use of opioids in 
cancer pain management are relatively well established 
[17] and adopted in clinical practice in Korea, use of opi-
oids for noncancer pain treatment (including spinal dis-
orders) is estimated to be much lower. As indicated by the 
investigators’ survey responses, there is need for more lo-
cal clinical data and development of improved guidelines 
for use of opioids to treat spinal pain in Korea.
The NRS is a well-validated and preferred unidimen-
sional self-report tool for pain assessment [23,24]; thus, it 
should be used more widely in clinical settings. Neverthe-
less, in this study, NRS pain assessments were only record-
ed for 24.0% of the 2,468 patients. Because the suitability 
of pain alleviation by opioid therapy cannot be fully sup-
ported or rejected unless appropriate, standardized meth-
ods for pain measurement are applied [5,13,15,16,25-27]. 
Our data imply that additional education is needed on 
regular assessment and documentation of pain in clinical 
practice.
We note several limitations inherent to the nature of the 
study. First, we only assessed patients who received opioid 
treatment for spinal disorders and did not examine the 
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entire spinal disorder population. Thus, it is difficult to 
analyze global factors that affect clinical decisions related 
to spinal pain management, for example, the data col-
lected do not permit us to explain how clinical decisions 
were made on whether to prescribe opioid analgesics or 
to choose other treatment modalities. Second, certain pa-
tients were receiving ongoing opioid treatment at the time 
of data collection and had not yet completed the full treat-
ment course. For such patients, data for the entire treat-
ment duration and ultimate outcomes of opioid treatment 
were not available at the point of data collection. Third, 
reporting of adverse events or ADRs may have been in-
complete owing to the retrospective nature of the study.
Conclusions 
To the best of our knowledge, this is the first large-scale 
report on patterns of opioid treatment in 2468 patients 
with spinal disorders in university hospitals across Korea. 
The findings demonstrated an overall alignment of cur-
rent practices in Korea with international guidelines for 
opioid-based management of spinal pain. In particular, 
the results may be a valuable local source of preliminary 
data for treatment guidelines on spinal disorders in Ko-
rea. The findings underscore the importance of objective 
measurements and appropriate documentation of pain to 
guide opioid usage for management of spinal pain in Ko-
rea.
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